COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Long-Term Safety of Budesonide for Patients With Chronic Rhinosinusitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03584178
Recruitment Status : Recruiting
First Posted : July 12, 2018
Last Update Posted : September 20, 2019
Information provided by (Responsible Party):
Amin Javer, St. Paul's Hospital, Canada

Brief Summary:
Chronic Rhinosinusitis (CRS) is a common disorder of the nose. The current practice at St Paul's Sinus Centre is to prescribe budesonide via the mucosal atomization device or impregnated saline irrigation. Both have shown to be a safe method of administration. A previous study demonstrated a 6% elevation in intraocular pressure and 3% prevalence of asymptomatic AdrenoCorticoTropic Hormone-Axis (ACTH) suppression. However, a baseline measurement was not conducted to ascertain the correlation of these findings with the medication. Therefore, the investigators aim to conduct baseline measurements of IntraOcular Pressure (IOP), ACTH-axis function, and Dual Energy X-ray Absorptiometry (DEXA) scan and obtaining regular measurements of these variables within a 12-month period to further ascertain these previous findings.

Condition or disease Intervention/treatment Phase
Sinusitis Device: Budesonide via MAD device Device: Budesonide via intranasals Saline Irrigation Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: The Long-Term Safety of Budesonide Via Mucosal Atomization Device and Impregnated Nasal Saline Irrigations for Patients With Chronic Rhinosinusitis - A Prospective Double Cohort Study.
Actual Study Start Date : September 5, 2018
Estimated Primary Completion Date : December 25, 2020
Estimated Study Completion Date : December 25, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sinusitis

Arm Intervention/treatment
Experimental: Mucosal Atomization Device
Budesonide via MAD Device
Device: Budesonide via MAD device
Delivery through Mucosal Atomization Device
Other Name: Budesonide via Mucosal Atomization Device

Experimental: Intranasals Saline Irrigation
Budesonide via Intranasals Saline Irrigation
Device: Budesonide via intranasals Saline Irrigation
delivery via nasal irrigation bottle
Other Name: Intranasals Saline Irrigation

Primary Outcome Measures :
  1. Sinonasal-Outcomes Test-22 (SNOT-22) Questionnaire [ Time Frame: 1 year ]
    This sinus-specific questionnaire is divided into three parts consisting of 22 questions that are related to sinus health and health-related quality of life. This questionnaire was developed to assess symptoms and quality of life in patients suffering from CRS with or without nasal polyposis. Each question is scored on an ordinal, categorical scale ranging from 0 to 5. Patients are instructed to indicate if symptoms are "absent (0)", "very mild (1)", "mild (2)", "moderate (3)", "severe (4)" or "as bad as it can be (5)". The highest score achievable on this questionnaire is 110 points. Higher scores indicate greater symptom severity and burden on daily life. In a validation survey of 2803 subjects, the SNOT-22 showed high internal consistency, test-retest reliability and validity. The SNOT-22 was found to sufficiently distinguish between patients with CRS and healthy controls (P<0.0001, t=85.3).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged between 19 years and above
  2. Patients with chronic or recurrent sinusitis (as defined by the American Academy of Otolaryngology) with nasal polyposis
  3. Patients with an upcoming Functional Endoscopic Sinus Surgery (FESS) procedure
  4. Patients being prescribed INCS for the first time following FESS

Exclusion Criteria:

  1. Individuals unable to understand the purpose, methods and conduct of this study
  2. Patients unwilling to provide informed consent
  3. Patients with significant comorbidities (such as tumour, CF, wegeners granulomatosis, immunocompromised)
  4. Patients with a history of pituitary disease
  5. Patients with a known hypersensitivity to cortisol, corticotropin, or cosyntropin
  6. Patients with history of glaucoma or cataracts
  7. Recent use of systemic corticosteroids such as prednisone (within last 3 months)
  8. Patients that are not adherent to budesonide via MAD/INSI treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03584178

Layout table for location contacts
Contact: Amin Javer, MD 6048069926
Contact: Sara Derikvand, PhD 6048069926

Layout table for location information
Canada, British Columbia
St Paul Hospital Recruiting
Vancouver, British Columbia, Canada, V6Z 1Y6
Contact: Sara Derikvand, PhD    6048069926   
Contact: Amin Javer, MD    6048069926   
Principal Investigator: Amin R Javer, MD         
Sponsors and Collaborators
St. Paul's Hospital, Canada
Layout table for investigator information
Principal Investigator: Amin Javer, MD University of British Columbia
Layout table for additonal information
Responsible Party: Amin Javer, Director, St. Paul's Sinus Centre, St. Paul's Hospital, Canada Identifier: NCT03584178    
Other Study ID Numbers: H18-00458
First Posted: July 12, 2018    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amin Javer, St. Paul's Hospital, Canada:
Intraocular pressure
Bone density
Additional relevant MeSH terms:
Layout table for MeSH terms
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists